Table 1.
Characteristics of eligible studies
| Author (reference), year (country) | Study design | Quality score | Exclusion criteria | Newborns by Caesarean/vaginal, n/n | HbV+ newborns by Caesarean/vaginal, n/n | HBeAg+/>106 copies/ml, % | Given HBIG/ vaccine,% | HBIG dosing | Vaccine schedule | Follow-up | Caesarean section, % | Forceps or vacuum, % | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elective | Urgent | ||||||||||||
| Lee et al (19), 1988 (China) | Retrospective cohort | 6/9 | Not reported | 62/385 | 6/96 | 100/– | 76/100 | 50 IU ≤ 9 h ± at 1 month | 2 weeks, 1, 2 months, 1 year | 6 months | Not reported | Not reported | Not reported |
| Wang et al (20), 2002 (China) | Retrospective cohort | 7/9 | Not reported | 117/184 | 11/15 | Not reported | All since 1997 | 100 IU | 1, 2, 7 months | 12 months | Not reported | Not reported | 13 |
| Zou et al (22), 2010 (China) | Retrospective cohort/ abstract | 7/9 | Not reported | 283/286 | 12/17 | 100/– | 100/100 | 200 IU ≤ 12 h,2 weeks | Delivery, 1, 6 months | 12 months | 33 | 17 | Not reported |
| Dwivedi et al (17), 2011 (India) | Retrospective cohort | 7/9 | Not reported | 11/25 | 2/15 | 41/– | Not reported | Not reported | Not reported | At delivery | 11 | 19 | Not reported |
| Lu et al (9), 2012 (Taiwan) | Retrospective cohort/abstract | 8/9 | Not reported | 44/132 | 1/18 | 100 | 74/– | Not reported | Not reported | Not stated | Not reported | Not reported | Not reported |
| Chen et al (16), 2013 (China) | Retrospective cohort | 4/9 | HIV, HCV, TB, Ig, nuc | 98/73 | 21/14 | 35/29 | 100/100 | 200 IU ≤ 24 h | ≤ 24 h, 1, 6 months | At delivery | Not reported | Not reported | Not reported |
| Guo et al (18), 2013 (China) | Case control | 7/9 | Not reported | 584/549 | 29/72 | 39/– | 69/1 | Not reported | Not reported | 24 h | Not reported | Not reported | Not reported |
| Hu et al (6), 2013 (China) | Retrospective cohort | 7/9 | HIV, HCV, nuc, threatened abortion | 285/261 | 14/6 | 25/– | 51/100 | No dose, ≤24 h | 3 doses total | 1–7 years | 52 | 0 | Not reported |
| Pan et al (7), 2013 (China) | Retrospective cohort | 9/9 | HIV, HCV, HDV, nuc/ IFN within 6 months | 736/673 | 17/23 | 55/48 | 100/100 | 200 IU ≤ 6 h | Delivery, 1, 6 months | 7–12 months | 35 | 17 | Not reported |
| Wen et al (21), 2013 (Taiwan) | Retrospective cohort | 8/9 | HIV | 132/171 | 3/7 | 27/– | 75*/100 | 100 IU ≤ 24 h | Within 1 week, 1, 6 months | 3 years | Not reported | Not reported | Not reported |
*
All hepatitis B e antigen-positive (HBeAg+) women received hepatitis B immune globulin (HBIG) and HBeAg-negative women were given the option to purchase HBIG. HCV Hepatitis C virus; Ig Immunoglobulin; HDV Hepatitis D virus; IFN Interferon; nuc Nucleos(t)ide analogue; TB Tuberculosis